| Bioactivity | NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research[1]. | ||||||||||||
| Invitro | NFATc1-IN-1 (compound A04) (0-2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption[1].NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | NFATc1-IN-1 | ||||||||||||
| CAS | 1912422-56-0 | ||||||||||||
| Formula | C13H8F2INO2 | ||||||||||||
| Molar Mass | 375.11 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Chen CL, et al. Design, synthesis and SARs of novel salicylanilides as potent inhibitors of RANKL-induced osteoclastogenesis and bone resorption. Eur J Med Chem. 2016 Jul 19;117:70-84. |
NFATc1-IN-1
CAS: 1912422-56-0 F: C13H8F2INO2 W: 375.11
NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.